1. Home
  2. KNDI vs ACRV Comparison

KNDI vs ACRV Comparison

Compare KNDI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.79

Market Cap

67.8M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

74.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
ACRV
Founded
2002
2018
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
74.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
KNDI
ACRV
Price
$0.79
$2.41
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$14.67
AVG Volume (30 Days)
254.5K
430.9K
Earning Date
03-13-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$104,035,613.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$1.05
52 Week High
$1.81
$8.00

Technical Indicators

Market Signals
Indicator
KNDI
ACRV
Relative Strength Index (RSI) 31.09 52.99
Support Level $0.79 $2.12
Resistance Level $0.88 $2.59
Average True Range (ATR) 0.09 0.19
MACD -0.01 -0.01
Stochastic Oscillator 1.39 47.54

Price Performance

Historical Comparison
KNDI
ACRV

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: